American Oncology Network, LLC (“AON” or the “Company”), a rapidly
growing network of community-based oncology practices, and Digital
Transformation Opportunities Corp. (Nasdaq: DTOC) (“DTOC”), a
special purpose acquisition company focused on the healthcare
industry, announced today the completion of their previously
announced business combination (the “Business Combination”).
The combined company has been renamed American Oncology Network,
Inc., and its common stock is expected to commence trading on the
Nasdaq Stock Market LLC ("Nasdaq") under the new ticker symbol
“AONC” on September 21, 2023. The Business Combination was approved
at a special meeting of DTOC’s stockholders on September 19,
2023.
In just five years since its inception in 2018, AON has grown to
include over 1,500 employees and over 200 providers in more than 75
clinics serving over 450,000 patients nationwide. AON practices
have access to fully integrated ancillary services such as a
specialty pharmacy, lab and pathology, radiation therapy, and
imaging. These services promote clinical coordination and seamless
communication throughout all stages of the care process. AON
practices deliver high-quality patient care by sharing resources
and expertise across the network, providing access to leading
clinical trials, staying at the forefront of clinical innovation,
and advocating for their patients and the profession of community
oncology.
The DTOC partnership and recent strategic investment from AEA
Growth, a leading global investment firm, will help further AON’s
goals of supporting community oncology practices and improving the
patient experience by unlocking further growth through continuing
to add new providers to the AON network, scaling ancillary
services, introducing new service offerings, and expanding AON’s
existing services to address the broader oncology market.
“Today is an important milestone for AON and celebrates our
team’s hard work and dedication, which have been the keys to our
growth and success,” said Todd Schonherz, Chief Executive Officer
of AON. “AON is committed more than ever to expanding our reach and
advancing cancer care in communities across the nation where too
often patients experience accessibility barriers.”
“We are proud of our successful partnership with AON and look
forward to seeing the company’s profound impact enable advanced
treatment options, clinical research, and comprehensive care
options nationwide,” said Kevin Nazemi, Chief Executive Officer of
DTOC.
The combined company will continue to be led by AON’s Chief
Executive Officer, Todd Schonherz; Chief Financial Officer, David
Gould; and Chief Medical Officer, Dr. Stephen “Fred” Divers.
Paul Hastings LLP served as legal advisor to DTOC. Woolery &
Co. PLLC and Dentons US LLP served as legal advisors to AON.
About American Oncology Network
The American Oncology Network (AON) (Nasdaq: AONC) is an
alliance of physicians and seasoned healthcare leaders partnering
to ensure the long-term success of community oncology and other
specialties. Launched in 2018, the rapidly expanding AON network
represents 109 physicians and 86 nurse practitioners and physician
assistants practicing across 19 states. The executive management
team of AON encompasses more than four decades of oncology practice
management experience, enabling physicians to focus on what matters
most — providing the highest quality care for patients. Learn more
at www.aoncology.com.
About DTOC
Digital Transformation Opportunities Corp. is a blank check
company, led by Kevin Nazemi, Co-Founder and former Co-CEO of Oscar
Health, formed for the purpose of effecting a merger, capital stock
exchange, asset acquisition, stock purchase, reorganization or
similar business combination with one or more businesses. DTOC’s
Board of Directors includes Kevin Nazemi, Brad Fluegel (former
Chief Strategy Officer of Walgreens and Anthem), Jim Moffatt
(former Vice Chairman and Global CEO of Deloitte Consulting), and
Heather Zynczak (former Chief Marketing Officer of Pluralsight and
Domo). DTOC is focused on businesses operating in the healthcare
industry. To learn more about Digital Transformation Opportunities
Corp., visit www.dtocorp.com.
About AEA Growth
AEA Growth provides technology-enabled, healthcare and software
companies with flexible capital and operational resources to
accelerate growth. AEA Growth targets investments in
category-leading, capital-efficient businesses with strong customer
advocacy.
AEA Growth is part of AEA Investors LP. AEA Investors was
founded in 1968 by the Rockefeller, Mellon and Harriman family
interests and S.G. Warburg & Co. as a private investment
vehicle for a select group of industrial family offices with
substantial assets. AEA has an extraordinary global network built
over many years which includes leading industrial families,
business executives and leaders; many of whom invest with AEA as
active individual investors and/or join its portfolio company
boards or act in other advisory roles. Today, AEA’s approximately
120 investment professionals operate globally with offices in New
York, Stamford, San Francisco, London, Munich and Shanghai. The
firm manages funds that have approximately $19 billion of invested
and committed capital including the leveraged buyouts of middle
market companies and small business companies, growth capital and
private investments.
For more information, please contact:
For AON:David Gould, Chief Financial
OfficerDavid.Gould@aoncology.com
For DTOC:Kyle Francis, Chief Financial
Officerkyle@dtocorp.com
Forward-Looking Statements
Certain statements in this press release are forward-looking
statements. Forward-looking statements generally relate to future
events including future financial or operating performance of
American Oncology Network, Inc. (“New AON”). Forward-looking
statements generally relate to future events or New AON’s future
financial or operating performance. For example, projections of
future revenue and other metrics are forward-looking statements. In
some cases, you can identify forward-looking statements by
terminology such as “may”, “should”, “expect”, “intend”, “will”,
“estimate”, “anticipate”, “believe”, “predict”, “potential” or
“continue”, or the negatives of these terms or variations of them
or similar terminology. Such forward-looking statements are subject
to risks, uncertainties, and other factors that could cause actual
results to differ materially from those expressed or implied by
such forward-looking statements.
These forward-looking statements are based upon estimates and
assumptions that, while considered reasonable by New AON and its
management, are inherently uncertain and are inherently subject to
risks, variability and contingencies, many of which are beyond New
AON’s control. Factors that may cause actual results to differ
materially from current expectations include, but are not limited
to: (1) the ability to recognize the anticipated benefits of the
Business Combination, which may be affected by, among other things,
competition, the ability of the combined company to grow and manage
growth profitably, maintain key relationships and retain its
management and key employees; (2) costs related to the Business
Combination; (3) changes in applicable laws or regulations; (4) the
possibility that New AON may be adversely affected by other
economic, business, and/or competitive factors; (5) New AON’s
estimates of expenses and profitability; and (6) other risks and
uncertainties set forth in the section entitled “Risk Factors” and
“Cautionary Note Regarding Forward-Looking Statements” in New AON’s
final prospectus relating to the Business Combination dated July
18, 2023 filed with the SEC, and in subsequent filings with the
SEC. New AON cautions that the foregoing list of factors is not
exclusive or exhaustive and investors should not place undue
reliance upon any forward-looking statements, including
projections, which speak only as of the date made. If any of these
risks materialize or New AON’s assumptions prove incorrect, actual
results could differ materially from the results implied by these
forward-looking statements. There may be additional risks that New
AON does not presently know or that New AON currently believes are
immaterial that could also cause actual results to differ from
those contained in the forward-looking statements. In addition,
forward-looking statements reflect New AON’s expectations, plans or
forecasts of future events and views as of the date of this
communication. New AON anticipates that subsequent events and
developments will cause New AON’s assessments to change. However,
while New AON may elect to update these forward-looking statements
at some point in the future, New AON specifically disclaims any
obligation to do so, unless required by applicable law. These
forward-looking statements should not be relied upon as
representing New AON’s assessments as of any date subsequent to the
date of this communication. New AON does not give any assurance
that New AON will achieve its expectations. Accordingly, undue
reliance should not be placed upon the forward-looking
statements.
American Oncology Network (NASDAQ:AONC)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025
American Oncology Network (NASDAQ:AONC)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025